Catalog No.
DHC09604
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein
Concentration
5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P04626
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MGAH-22, CAS: 1350624-75-7
Clone ID
Margetuximab
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial, PMID: 33480963
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial, PMID: 32653053
Margetuximab for the treatment of HER2-positive metastatic breast cancer, PMID: 33238772
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma, PMID: 33263418
Margetuximab, PMID: 33355736
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors, PMID: 28119295
Antibodies to watch in 2020, PMID: 31847708
Antibodies to watch in 2021, PMID: 33459118
Margetuximab-cmkb, PMID: 33821931
Novel HER2-targeted therapies for HER2-positive metastatic breast cancer, PMID: 32721042
Margetuximab: First Approval, PMID: 33761116
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies, PMID: 32368385
Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options, PMID: 33149670
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217), PMID: 32487035
Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab, PMID: 34159226
Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives, PMID: 33447230
Highlights from the 2019 San Antonio Breast Cancer Symposium, PMID: 32609664
Super Trastuzumab Extends PFS in Late-Line Breast Cancer, PMID: 31175130
What therapies are on the horizon for HER2 positive breast cancer?, PMID: 31448640
Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer, PMID: 31656319
Current and Future Management of HER2-Positive Metastatic Breast Cancer, PMID: 34077236
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies, PMID: 34115243
New developments in metastatic breast cancer: integrating recent data into clinical practice, PMID: 24892840
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era, PMID: 34454323
For research use only. Not for human or drug use.
